Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 12, 2012 - Issue 5
Submit an article Journal homepage
82
Views
2
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Retinoblastoma protein determines aggressiveness in triple-negative breast cancer

Jimmy Jacob Division of Cancer, Department of Surgery and Cancer, 5th Floor, MRC Cyclotron Building, Imperial College, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK; Division of Cancer, Department of Surgery and Cancer, 5th Floor, MRC Cyclotron Building, Imperial College, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK. [email protected]
,
Adam E Frampton HPB Surgical Unit, Department of Surgery and Cancer, Imperial College, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK; HPB Surgical Unit, Department of Surgery and Cancer, Imperial College, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK
,
Leandro Castellano Division of Cancer, Department of Surgery and Cancer, 5th Floor, MRC Cyclotron Building, Imperial College, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK; Division of Cancer, Department of Surgery and Cancer, 5th Floor, MRC Cyclotron Building, Imperial College, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK
,
Justin Stebbing Department of Oncology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, 1st Floor, E Wing, Fulham Palace Road, London, W6 8RF, UK; Department of Oncology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, 1st Floor, E Wing, Fulham Palace Road, London, W6 8RF, UK
&
Jonathan Krell Division of Cancer, Department of Surgery and Cancer, 5th Floor, MRC Cyclotron Building, Imperial College, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK; Division of Cancer, Department of Surgery and Cancer, 5th Floor, MRC Cyclotron Building, Imperial College, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK
Pages 581-584 | Published online: 10 Jan 2014

References

  • Arima Y, Hayashi H, Sasaki M et al. Induction of ZEB by inactivation of RB is a key determinant of the mesenchymal phenotype of breast cancer. J. Biol. Chem.287(11), 7896–7906 (2012).
  • Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev.22(7), 894–907 (2008).
  • Wellner U, Schubert J, Burk UC et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol.11(12), 1487–1495 (2009).
  • Graham TR, Zhau HE, Odero-Marah VA et al. Insulin-like growth factor-I-dependent upregulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res.68(7), 2479–2488 (2008).
  • Uhlmann S, Zhang JD, Schwager A et al. miR-200bc/429 cluster targets PLC[gamma]1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene29(30), 4297–4306 (2010).
  • Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop – a motor of cellular plasticity in development and cancer? EMBO Rep.11(9), 670–677 (2010).
  • Schliekelman MJ, Gibbons DL, Faca VM et al. Targets of the tumor suppressor miR-200 in regulation of the epithelial–mesenchymal transition in cancer. Cancer Res.71(24), 7670–7682 (2011).
  • Wellner U, Brabletz T, Keck T. ZEB1 in pancreatic cancer. Cancers2(3), 1617–1628 (2010).
  • Rodler E, Korde L, Gralow J. Current treatment options in triple negative breast cancer. Breast Dis.32(1–2), 99–122 (2010).
  • O’Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med.364(3), 205–214 (2011).
  • Reeder-Hayes KE, Carey LA, Sikov WM. Clinical trials in triple negative breast cancer. Breast Dis.32(1–2), 123–136 (2010).
  • Du W, Searle JS. The RB pathway and cancer therapeutics. Curr. Drug Targets10(7), 581–589 (2009).
  • Morris EJ, Dyson NJ. Retinoblastoma protein partners. Adv. Cancer Res.82, 1–54 (2001).
  • Arima Y, Hayashi N, Hayashi H et al. Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int. J. Cancer130(11), 2568–2579 (2012).
  • Leonard JP, Lacasce AS, Smith MR et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood doi:10.1182/blood-2011–10–388298 (2012) (Epub ahead of print).
  • Roberts PJ, Bisi JE, Strum JC et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J. Natl Cancer Inst.104(6), 476–487 (2012).
  • Volinia S, Galasso M, Sana ME et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc. Natl Acad. Sci. USA109(8), 3024–3029 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.